These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 3322781)

  • 1. Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.
    Harron DW; Brogden RN
    Drugs; 1987 Dec; 34(6):617-47. PubMed ID: 3322781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.
    Bryson HM; Palmer KJ; Langtry HD; Fitton A
    Drugs; 1993 Jan; 45(1):85-130. PubMed ID: 7680987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines for the use of propafenone in treating supraventricular arrhythmias.
    Kishore AG; Camm AJ
    Drugs; 1995 Aug; 50(2):250-62. PubMed ID: 8521758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal.
    Capucci A; Boriani G
    Drug Saf; 1995 Jan; 12(1):55-72. PubMed ID: 7741984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propafenone: a novel type Ic antiarrhythmic agent.
    Parker RB; McCollam PL; Bauman JL
    DICP; 1989 Mar; 23(3):196-202. PubMed ID: 2655298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moricizine. A review of its pharmacological properties, and therapeutic efficacy in cardiac arrhythmias.
    Fitton A; Buckley MT
    Drugs; 1990 Jul; 40(1):138-67. PubMed ID: 2202581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165.
    Hashimoto K; Ishii M; Komori S; Mitsuhashi H
    Heart Vessels; 1985 Feb; 1(1):29-35. PubMed ID: 2419304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propafenone: an effective agent for the management of supraventricular arrhythmias.
    Grant AO
    J Cardiovasc Electrophysiol; 1996 Apr; 7(4):353-64. PubMed ID: 8777484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Propafenone and flecainide in the therapy of ventricular arrhythmias].
    Paperini L; Davini A; Lattanzi F; Topi A; Reisenhofer B; Squarcini G; Paci A; Topi PL
    Minerva Cardioangiol; 1995 Oct; 43(10):449-57. PubMed ID: 8819814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with propafenone for cardiac arrhythmias in the young.
    Heusch A; Kramer HH; Krogmann ON; Rammos S; Bourgeous M
    Eur Heart J; 1994 Aug; 15(8):1050-6. PubMed ID: 7527342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.
    Brogden RN; Todd PA
    Drugs; 1987 Aug; 34(2):151-87. PubMed ID: 3304965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained therapeutic efficacy and safety of oral propafenone for treatment of chronic ventricular arrhythmias: a 2-year experience.
    Dinh H; Baker BJ; de Soyza N; Murphy ML
    Am Heart J; 1988 Jan; 115(1 Pt 1):92-6. PubMed ID: 3336989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Holmes B; Heel RC
    Drugs; 1985 Jan; 29(1):1-33. PubMed ID: 3882390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction.
    Touboul P; Moleur P; Mathieu MP; Vrancea F; Ferry S; Kirkorian G; Atallah G; Marchand A; Stahl C; Zoheir F
    Eur Heart J; 1988 Nov; 9(11):1188-93. PubMed ID: 3234410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Propafenone: a new antiarrhythmic agent.
    Chow MS; Lebsack C; Hilleman D
    Clin Pharm; 1988 Dec; 7(12):869-77. PubMed ID: 3061720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class IC drugs: propafenone and flecainide.
    Puech P; Gagnol JP
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():549-53. PubMed ID: 2125832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propafenone versus disopyramide for treatment of chronic symptomatic ventricular arrhythmias. A multicenter study.
    Jonason T; Ringqvist I; Bandh S; Nilsson G; Nilsson H; Lidell C; Bjerle P; Olofsson BO
    Acta Med Scand; 1988; 223(6):515-23. PubMed ID: 3291557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of oral propafenone in the treatment of arrhythmias in infants and children (European retrospective multicenter study). Working Group on Pediatric Arrhythmias and Electrophysiology of the Association of European Pediatric Cardiologists.
    Janousek J; Paul T
    Am J Cardiol; 1998 May; 81(9):1121-4. PubMed ID: 9605053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The treatment of arrhythmias in infants and children using propafenone].
    Dressler F; Grävinghoff L; Grütte E; Jüngst BK; Liersch R; Nomayo H; Puls I; Rautenburg HW; Schmaltz A; Schumacher G
    Monatsschr Kinderheilkd; 1985 Mar; 133(3):154-7. PubMed ID: 4010670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of the newer antiarrhythmic agents.
    Gillis AM; Kates RE
    Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.